Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 18, 2025 04:27PM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 21, 2025 04:35PM Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM
Jun 18, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Jan 30, 2025 06:40AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM
Sep 12, 2024 08:30AM
Aug 15, 2024 07:45AM
Aug 15, 2024 07:45AM Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Aug 13, 2024 07:45AM
Jun 25, 2024 09:20AM
Jun 25, 2024 09:20AM
May 21, 2024 09:00AM
May 8, 2024 07:00AM
Apr 1, 2024 08:00AM
Mar 6, 2024 06:45AM Cingulate to Attend DCAT Week 2024 in New York City
Feb 13, 2024 06:46AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All